source
- ADC Therapeutics' Zynlonta confirmatory trial shows higher death rates, clouding full approval prospectsADC Therapeutics is pursuing full FDA approval for its antibody-drug conjugate Zynlonta in patients with relapsed or refractory diffuse large B-cell lymphoma. In the confirmatory study presented,…
- Revolution Medicines eyes broader use of daraxonrasib pending FDA submissionRevolution Medicines' daraxonrasib has not yet been approved for metastatic pancreatic cancer after chemotherapy, but a recent ASCO plenary presentation generated strong interest. Analysts expect…